Research Analysts Set Expectations for AXSM Q1 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Thursday, February 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($1.06) per share for the quarter, down from their previous estimate of ($0.85). HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($1.93) EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $2.43 EPS and Q4 2026 earnings at $3.82 EPS.

A number of other analysts have also issued reports on the stock. Robert W. Baird set a $132.00 price target on shares of Axsome Therapeutics in a research note on Monday, February 3rd. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Royal Bank of Canada boosted their price target on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $176.00 price target on the stock. Finally, Bank of America upped their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $158.79.

Axsome Therapeutics Stock Down 2.8 %

Shares of NASDAQ AXSM opened at $127.09 on Monday. The firm has a market cap of $6.20 billion, a price-to-earnings ratio of -21.22 and a beta of 1.05. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. Axsome Therapeutics has a 52-week low of $64.11 and a 52-week high of $139.13. The business’s 50 day moving average is $102.78 and its two-hundred day moving average is $95.62.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 22.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Raiffeisen Bank International AG acquired a new position in Axsome Therapeutics during the fourth quarter worth $51,000. Assetmark Inc. acquired a new stake in shares of Axsome Therapeutics in the fourth quarter valued at approximately $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $64,000. Aquatic Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $76,000. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $86,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.